Nakagawa K, Kamezaki T, Shibata Y, Tsunoda T, Meguro K, Nose T
Department of Neurological Surgery, University of Tsukuba, Ibaraki.
Neurol Med Chir (Tokyo). 1995 Jan;35(1):22-7. doi: 10.2176/nmc.35.22.
The use of autologous lymphokine-activated killer (LAK) cells to treat malignant brain tumors was evaluated in 10 patients, one with metastatic malignant melanoma and nine with malignant glioma. LAK cells were obtained by culturing autologous peripheral blood lymphocytes with human recombinant interleukin-2 (rIL-2) for 7-28 days. All patients underwent surgery to remove as much tumor as possible and an Ommaya reservoir was implaced in the tumor cavity. Two of the 10 patients had received radiotherapy elsewhere, so were treated with LAK cells alone. Eight patients were treated with a combination of LAK cells and radiotherapy, using 1.8-2.0 Gy fractions given five times a week with a total dosage between 54 and 65 Gy. LAK cells and rIL-2 were injected to the tumor cavity via the Ommaya reservoir once a week for inpatients and once a month for outpatients. The duration of the LAK therapy ranged from 3 to 23 months (mean 13.7 mos). Neuroimaging evaluation revealed two complete responses, three partial responses, four no changes, and one progressive disease. In one patient with pontine glioma, the Karnofsky performance score was raised from 20 to 60. There were no side effects after the injection of LAK cells and rIL-2. The results suggest low-dose LAK therapy is a useful and safe treatment modality for malignant brain tumors.
对10例患者进行了自体淋巴因子激活的杀伤细胞（LAK细胞）治疗恶性脑肿瘤的评估，其中1例为转移性恶性黑色素瘤，9例为恶性胶质瘤。通过用人重组白细胞介素-2（rIL-2）培养自体外周血淋巴细胞7至28天来获取LAK细胞。所有患者均接受手术以尽可能多地切除肿瘤，并在肿瘤腔内植入Ommaya储液器。10例患者中有2例在其他地方接受过放疗，因此仅接受LAK细胞治疗。8例患者接受了LAK细胞与放疗的联合治疗，采用每周5次、每次1.8 - 2.0 Gy的分割剂量，总剂量在54至65 Gy之间。住院患者每周通过Ommaya储液器向肿瘤腔内注射一次LAK细胞和rIL-2，门诊患者每月注射一次。LAK治疗的持续时间为3至23个月（平均13.7个月）。神经影像学评估显示2例完全缓解，3例部分缓解，4例无变化，1例疾病进展。在1例桥脑胶质瘤患者中，卡氏功能状态评分从20提高到了60。注射LAK细胞和rIL-2后未出现副作用。结果表明，低剂量LAK治疗是一种治疗恶性脑肿瘤的有效且安全的治疗方式。
